Header cover image
  • Investing Ideas
  • Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential

Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential

Results

4

0 new

Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.

4 companies

Galderma Group

Market Cap: CHF 36.8b

Operates as a dermatology company worldwide.

GALD

CHF 156.85

7D

-1.3%

1Y

99.7%

Novartis

Market Cap: CHF 226.7b

Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

NOVN

CHF 118.82

7D

-1.5%

1Y

31.1%

Sandoz Group

Market Cap: CHF 29.1b

Develops, manufactures, and markets generic and biosimilars worldwide.

SDZ

CHF 67.16

7D

1.6%

1Y

106.5%

Lonza Group

Market Cap: CHF 38.0b

Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

LONN

CHF 543.40

7D

5.1%

1Y

0.8%